This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weigel, L. M.
Right arrow Articles by Tenover, F. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weigel, L. M.
Right arrow Articles by Tenover, F. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2001, p. 3517-3523, Vol. 45, No. 12
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.12.3517-3523.2001

Genetic Analyses of Mutations Contributing to Fluoroquinolone Resistance in Clinical Isolates of Streptococcus pneumoniae

L. M. Weigel,1,* G. J. Anderson,1 R. R. Facklam,2 and F. C. Tenover1

Division of Healthcare Quality Promotion1 and Division of Bacterial and Mycotic Diseases,2 National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333

Received 10 April 2001/Returned for modification 22 July 2001/Accepted 23 September 2001

Twenty-one clinical isolates of Streptococcus pneumoniae showing reduced susceptibility or resistance to fluoroquinolones were characterized by serotype, antimicrobial susceptibility, and genetic analyses of the quinolone resistance-determining regions (QRDRs) of gyrA, gyrB, parC, and parE. Five strains were resistant to three or more classes of antimicrobial agents. In susceptibility profiles for gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin, 14 isolates had intermediate- or high-level resistance to all fluoroquinolones tested except gemifloxacin (no breakpoints assigned). Fluoroquinolone resistance was not associated with serotype or with resistance to other antimicrobial agents. Mutations in the QRDRs of these isolates were more heterogeneous than those previously reported for mutants selected in vitro. Eight isolates had amino acid changes at sites other than ParC/S79 and GyrA/S81; several strains contained mutations in gyrB, parE, or both loci. Contributions to fluoroquinolone resistance by individual amino acid changes, including GyrB/E474K, ParE/E474K, and ParC/A63T, were confirmed by genetic transformation of S. pneumoniae R6. Mutations in gyrB were important for resistance to gatifloxacin but not moxifloxacin, and mutation of gyrA was associated with resistance to moxifloxacin but not gatifloxacin, suggesting differences in the drug-target interactions of the two 8-methoxyquinolones. The positions of amino acid changes within the four genes affected resistance more than did the total number of QRDR mutations. However, the effect of a specific mutation varied significantly depending on the agent tested. These data suggest that the heterogeneity of mutations will likely increase as pneumococci are exposed to novel fluoroquinolone structures, complicating the prediction of cross-resistance within this class of antimicrobial agents.

* Corresponding author. Mailing address: Division of Healthcare Quality Promotion (G-08), Centers for Disease Control and Prevention, 1600 Clifton Rd., N.E., Atlanta, GA 30333. Phone: (404) 639-1497. Fax: (404) 639-1381. E-mail: lweigel{at}cdc.gov.

Antimicrobial Agents and Chemotherapy, December 2001, p. 3517-3523, Vol. 45, No. 12
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.12.3517-3523.2001


This article has been cited by other articles:

  • Hoshino, K., Inoue, K., Murakami, Y., Kurosaka, Y., Namba, K., Kashimoto, Y., Uoyama, S., Okumura, R., Higuchi, S., Otani, T. (2008). In Vitro and In Vivo Antibacterial Activities of DC-159a, a New Fluoroquinolone. Antimicrob. Agents Chemother. 52: 65-76 [Abstract] [Full Text]  
  • Avrain, L., Garvey, M., Mesaros, N., Glupczynski, Y., Mingeot-Leclercq, M.-P., Piddock, L. J. V., Tulkens, P. M., Vanhoof, R., Van Bambeke, F. (2007). Selection of quinolone resistance in Streptococcus pneumoniae exposed in vitro to subinhibitory drug concentrations. J Antimicrob Chemother 60: 965-972 [Abstract] [Full Text]  
  • Billal, D. S., Fedorko, D. P., Yan, S. S., Hotomi, M., Fujihara, K., Nelson, N., Yamanaka, N. (2007). In vitro induction and selection of fluoroquinolone-resistant mutants of Streptococcus pyogenes strains with multiple emm types. J Antimicrob Chemother 59: 28-34 [Abstract] [Full Text]  
  • Touyama, M., Higa, F., Nakasone, C., Shinzato, T., Akamine, M., Haranaga, S., Tateyama, M., Nakasone, I., Yamane, N., Fujita, J. (2006). In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV. J Antimicrob Chemother 58: 1279-1282 [Abstract] [Full Text]  
  • Kim, H.-J., Seol, M.-J., Park, H.-S., Choi, D.-R., Seong, S.-K., Shin, H.-K., Kwak, J.-H. (2006). Antimicrobial activity of DW-224a, a new fluoroquinolone, against Streptococcus pneumoniae. J Antimicrob Chemother 57: 1256-1258 [Full Text]  
  • Ip, M., Chau, S. S. L., Chi, F., Qi, A., Lai, R. W. M. (2006). Rapid Screening of Fluoroquinolone Resistance Determinants in Streptococcus pneumoniae by PCR-Restriction Fragment Length Polymorphism and Single-Strand Conformational Polymorphism.. J. Clin. Microbiol. 44: 970-975 [Abstract] [Full Text]  
  • Varon, E., Houssaye, S., Grondin, S., Gutmann, L., the Groupe des Observatoires de la Resistance du P, (2006). Nonmolecular Test for Detection of Low-Level Resistance to Fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50: 572-579 [Abstract] [Full Text]  
  • Korzheva, N., Davies, T. A., Goldschmidt, R. (2005). Novel Ser79Leu and Ser81Ile Substitutions in the Quinolone Resistance-Determining Regions of ParC Topoisomerase IV and GyrA DNA Gyrase Subunits from Recent Fluoroquinolone-Resistant Streptococcus pneumoniae Clinical Isolates. Antimicrob. Agents Chemother. 49: 2479-2486 [Abstract] [Full Text]  
  • Shultz, T. R., White, P. A., Tapsall, J. W. (2005). In Vitro Assessment of the Further Potential for Development of Fluoroquinolone Resistance in Neisseria meningitidis. Antimicrob. Agents Chemother. 49: 1753-1760 [Abstract] [Full Text]  
  • Dupont, P., Aubry, A., Cambau, E., Gutmann, L. (2005). Contribution of the ATP Binding Site of ParE to Susceptibility to Novobiocin and Quinolones in Streptococcus pneumoniae. J. Bacteriol. 187: 1536-1540 [Abstract] [Full Text]  
  • Brown, S. D., Farrell, D. J., Morrissey, I. (2004). Prevalence and Molecular Analysis of Macrolide and Fluoroquinolone Resistance among Isolates of Streptococcus pneumoniae Collected during the 2000-2001 PROTEKT US Study. J. Clin. Microbiol. 42: 4980-4987 [Abstract] [Full Text]  
  • Pletz, M. W. R., McGee, L., Jorgensen, J., Beall, B., Facklam, R. R., Whitney, C. G., Klugman, K. P. (2004). Levofloxacin-Resistant Invasive Streptococcus pneumoniae in the United States: Evidence for Clonal Spread and the Impact of Conjugate Pneumococcal Vaccine. Antimicrob. Agents Chemother. 48: 3491-3497 [Abstract] [Full Text]  
  • Ling, J. M., Chan, E. W., Lam, A. W., Cheng, A. F. (2003). Mutations in Topoisomerase Genes of Fluoroquinolone-Resistant Salmonellae in Hong Kong. Antimicrob. Agents Chemother. 47: 3567-3573 [Abstract] [Full Text]  
  • Kawamura, Y., Fujiwara, H., Mishima, N., Tanaka, Y., Tanimoto, A., Ikawa, S., Itoh, Y., Ezaki, T. (2003). First Streptococcus agalactiae Isolates Highly Resistant to Quinolones, with Point Mutations in gyrA and parC. Antimicrob. Agents Chemother. 47: 3605-3609 [Abstract] [Full Text]  
  • Allen, G. P., Kaatz, G. W., Rybak, M. J. (2003). Activities of Mutant Prevention Concentration-Targeted Moxifloxacin and Levofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 47: 2606-2614 [Abstract] [Full Text]  
  • Price, L. B., Vogler, A., Pearson, T., Busch, J. D., Schupp, J. M., Keim, P. (2003). In Vitro Selection and Characterization of Bacillus anthracis Mutants with High-Level Resistance to Ciprofloxacin. Antimicrob. Agents Chemother. 47: 2362-2365 [Abstract] [Full Text]  
  • Hurtle, W., Lindler, L., Fan, W., Shoemaker, D., Henchal, E., Norwood, D. (2003). Detection and Identification of Ciprofloxacin-Resistant Yersinia pestis by Denaturing High-Performance Liquid Chromatography. J. Clin. Microbiol. 41: 3273-3283 [Abstract] [Full Text]  
  • Johnson, C. N., Benjamin, W. H. Jr., Moser, S. A., Hollingshead, S. K., Zheng, X., Crain, M. J., Nahm, M. H., Waites, K. B. (2003). Genetic Relatedness of Levofloxacin-Nonsusceptible Streptococcus pneumoniae Isolates from North America. J. Clin. Microbiol. 41: 2458-2464 [Abstract] [Full Text]  
  • Chang, S., Sievert, D. M., Hageman, J. C., Boulton, M. L., Tenover, F. C., Downes, F. P., Shah, S., Rudrik, J. T., Pupp, G. R., Brown, W. J., Cardo, D., Fridkin, S. K., the Vancomycin-Resistant Staphylococcus aureus Inv, (2003). Infection with Vancomycin-Resistant Staphylococcus aureus Containing the vanA Resistance Gene. NEJM 348: 1342-1347 [Full Text]  
  • Ince, D., Zhang, X., Silver, L. C., Hooper, D. C. (2003). Topoisomerase Targeting with and Resistance to Gemifloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 274-282 [Abstract] [Full Text]  
  • Alonso, R., Galimand, M., Courvalin, P. (2002). parC Mutation Conferring Ciprofloxacin Resistance in Streptococcus pyogenes BM4513. Antimicrob. Agents Chemother. 46: 3686-3687 [Full Text]  
  • Yokota, S.-i., Sato, K., Kuwahara, O., Habadera, S., Tsukamoto, N., Ohuchi, H., Akizawa, H., Himi, T., Fujii, N. (2002). Fluoroquinolone-Resistant Streptococcus pneumoniae Strains Occur Frequently in Elderly Patients in Japan. Antimicrob. Agents Chemother. 46: 3311-3315 [Abstract] [Full Text]  
  • Croisier, D., Chavanet, P., Lequeu, C., Ahanou, A., Nierlich, A., Neuwirth, C., Piroth, L., Duong, M., Buisson, M., Portier, H. (2002). Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J Antimicrob Chemother 50: 349-360 [Abstract] [Full Text]  
  • Madaras-Kelly, K. J., Daniels, C., Hegbloom, M., Thompson, M. (2002). Pharmacodynamic characterization of efflux and topoisomerase IV-mediated fluoroquinolone resistance in Streptococcus pneumoniae. J Antimicrob Chemother 50: 211-218 [Abstract] [Full Text]  
  • Weigel, L. M., Anderson, G. J., Tenover, F. C. (2002). DNA Gyrase and Topoisomerase IV Mutations Associated with Fluoroquinolone Resistance in Proteus mirabilis. Antimicrob. Agents Chemother. 46: 2582-2587 [Abstract] [Full Text]  
  • Ross, J. J., Worthington, M. G., Gorbach, S. L., Tillotson, G. S., Zhao, X., Drlica, K., Zhanel, G. G., Hoban, D. J., Chan, C. K., Hutchinson, J., Low, D. E., de Azavedo, J., Bast, D. (2002). Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia. NEJM 347: 65-67 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»